Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Non Operating Income (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Other Non Operating Income for 6 consecutive years, with -$105000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 165.62% to -$105000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$680000.0 through Dec 2025, down 900.0% year-over-year, with the annual reading at -$680000.0 for FY2025, 900.0% down from the prior year.
  • Other Non Operating Income hit -$105000.0 in Q4 2025 for Harmony Biosciences Holdings, up from -$106000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $26.2 million in Q4 2021 to a low of -$26.1 million in Q3 2021.
  • Historically, Other Non Operating Income has averaged -$32263.2 across 5 years, with a median of -$5000.0 in 2023.
  • Biggest five-year swings in Other Non Operating Income: soared 950.0% in 2022 and later crashed 7150.0% in 2024.
  • Year by year, Other Non Operating Income stood at $26.2 million in 2021, then crashed by 99.72% to $73000.0 in 2022, then tumbled by 106.85% to -$5000.0 in 2023, then soared by 3300.0% to $160000.0 in 2024, then tumbled by 165.62% to -$105000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for HRMY at -$105000.0 in Q4 2025, -$106000.0 in Q3 2025, and -$193000.0 in Q2 2025.